Albert Bourla, Pfizer CEO (Laurent Gillieron/Keystone via AP Images)

Pfiz­er says RSV shot to pro­tect in­fants may be avail­able by 2023-24 cold and flu sea­son

Pfiz­er’s vac­cine to pro­tect in­fants from RSV may be ap­proved be­fore the next cold and flu sea­son, the com­pa­ny said on Tues­day.

Reg­u­la­tors grant­ed RSVpreF, al­so known as PF-06928316, a pri­or­i­ty re­view for the pre­ven­tion of med­ical­ly at­tend­ed low­er res­pi­ra­to­ry tract ill­ness (MA-LR­TI) caused by RSV in in­fants. The shot would be ad­min­is­tered dur­ing preg­nan­cy to pro­tect in­fants from birth to 6 months old.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.